The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction

The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. Coronary artery obstruction is a rare but devasta...

Full description

Saved in:
Bibliographic Details
Published inJACC. Cardiovascular interventions Vol. 12; no. 13; pp. 1240 - 1252
Main Authors Khan, Jaffar M, Greenbaum, Adam B, Babaliaros, Vasilis C, Rogers, Toby, Eng, Marvin H, Paone, Gaetano, Leshnower, Bradley G, Reisman, Mark, Satler, Lowell, Waksman, Ron, Chen, Marcus Y, Stine, Annette M, Tian, Xin, Dvir, Danny, Lederman, Robert J
Format Journal Article
LanguageEnglish
Published United States 08.07.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction. Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images. Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR. BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk.
AbstractList The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study.OBJECTIVESThe BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study.Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction.BACKGROUNDCoronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction.Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images.METHODSSubjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images.Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR.RESULTSBetween February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR.BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk.CONCLUSIONSBASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk.
The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational device exemption trial was a prospective, multicenter, single-arm safety and feasibility study. Coronary artery obstruction is a rare but devastating complication of transcatheter aortic valve replacement (TAVR). Current stent-based preventative strategies are suboptimal. Bioprosthetic or native aortic scallop intentional laceration to prevent iatrogenic coronary artery obstruction during TAVR (BASILICA) is a novel transcatheter technique performed immediately before TAVR to prevent coronary artery obstruction. Subjects with severe native or bioprosthetic aortic valve disease at high or extreme risk for surgery, and at high risk of coronary artery obstruction, were included. The primary success endpoint was successful BASILICA and TAVR without coronary obstruction or reintervention. The primary safety endpoint was freedom from major adverse cardiovascular events. Data were independently monitored. Endpoints were independently adjudicated. A core laboratory analyzed computed tomography images. Between February 2018 and July 2018, 30 subjects were enrolled. Primary success was met in 28 (93%) subjects. BASILICA traversal and laceration was successful in 35 of 37 (95%) attempted leaflets. There was 100% freedom from coronary obstruction and reintervention. Primary safety was met in 21 (70%), driven by 6 (20%) major vascular complications related to TAVR but not BASILICA. There was 1 death at 30 days. There was 1 (3%) disabling stroke and 2 (7%) nondisabling strokes. Transient hemodynamic compromise was rare (7%) and resolved promptly with TAVR. BASILICA was feasible in both native and bioprosthetic valves. Hemodynamic compromise was uncommon. Safety was acceptable and needs confirmation in larger studies. BASILICA appears effective in preventing coronary artery obstruction from TAVR in subjects at high risk.
Author Lederman, Robert J
Satler, Lowell
Leshnower, Bradley G
Reisman, Mark
Chen, Marcus Y
Dvir, Danny
Rogers, Toby
Khan, Jaffar M
Eng, Marvin H
Waksman, Ron
Stine, Annette M
Babaliaros, Vasilis C
Paone, Gaetano
Tian, Xin
Greenbaum, Adam B
AuthorAffiliation d Medstar Washington Hospital Center, Washington, DC
e University of Washington, Seattle, Washington
c Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia
b Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan
a Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maiyland
AuthorAffiliation_xml – name: a Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maiyland
– name: c Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia
– name: b Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan
– name: e University of Washington, Seattle, Washington
– name: d Medstar Washington Hospital Center, Washington, DC
Author_xml – sequence: 1
  givenname: Jaffar M
  surname: Khan
  fullname: Khan, Jaffar M
  organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
– sequence: 2
  givenname: Adam B
  surname: Greenbaum
  fullname: Greenbaum, Adam B
  organization: Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan; Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia
– sequence: 3
  givenname: Vasilis C
  surname: Babaliaros
  fullname: Babaliaros, Vasilis C
  organization: Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia
– sequence: 4
  givenname: Toby
  surname: Rogers
  fullname: Rogers, Toby
  organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; Medstar Washington Hospital Center, Washington, DC
– sequence: 5
  givenname: Marvin H
  surname: Eng
  fullname: Eng, Marvin H
  organization: Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan
– sequence: 6
  givenname: Gaetano
  surname: Paone
  fullname: Paone, Gaetano
  organization: Center for Structural Heart Disease, Division of Cardiology, and Division of Cardiac Surgery, Henry Ford Health System, Detroit, Michigan
– sequence: 7
  givenname: Bradley G
  surname: Leshnower
  fullname: Leshnower, Bradley G
  organization: Structural Heart and Valve Center, Emory University Hospital, Atlanta, Georgia
– sequence: 8
  givenname: Mark
  surname: Reisman
  fullname: Reisman, Mark
  organization: University of Washington, Seattle, Washington
– sequence: 9
  givenname: Lowell
  surname: Satler
  fullname: Satler, Lowell
  organization: Medstar Washington Hospital Center, Washington, DC
– sequence: 10
  givenname: Ron
  surname: Waksman
  fullname: Waksman, Ron
  organization: Medstar Washington Hospital Center, Washington, DC
– sequence: 11
  givenname: Marcus Y
  surname: Chen
  fullname: Chen, Marcus Y
  organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
– sequence: 12
  givenname: Annette M
  surname: Stine
  fullname: Stine, Annette M
  organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
– sequence: 13
  givenname: Xin
  surname: Tian
  fullname: Tian, Xin
  organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland
– sequence: 14
  givenname: Danny
  surname: Dvir
  fullname: Dvir, Danny
  organization: University of Washington, Seattle, Washington
– sequence: 15
  givenname: Robert J
  surname: Lederman
  fullname: Lederman, Robert J
  email: lederman@nih.gov
  organization: Cardiovascular Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: lederman@nih.gov
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31202947$$D View this record in MEDLINE/PubMed
BookMark eNpVkN9LwzAQx4Mozqn_gA-SR182kzRLGx-EOfwxqEy0-lrS9Dozuqam6cA3_3QjU1E4yF3uw_d7d0O029gGEDqhZEwJFeer8UqbZswIlWMShZjsoAOaxGIUCzLZ_ZMP0LDrVoQIImO2jwYRZYRJHh-gj-wV8NX0aZ7OZ1OcOaPqC_zgbNeC9mYD-L6vvdHQeHB43myg82apvLENtlX48KETClXjFFRVg8ep0uC2hLdBCjYBwdn05RHPrAuoe8eLovOu11_QEdqrVN3B8fd7iJ5vrrPZ3Shd3IaR0lHLhPAjDVyUPOY8LEF5UUxkKSaa06IokoQJSCSwqiqBlIUCkDHEkislGKU60gBxdIgut7ptX6yh_NrIqTpvnVmHiXKrTP6_05jXfGk3uRBCJjIKAmffAs6-9eEO-dp0GupaNWD7LmeMBzfGIhbQ079evyY_Z48-AYWpiuE
ContentType Journal Article
Copyright Published by Elsevier Inc.
Copyright_xml – notice: Published by Elsevier Inc.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.1016/j.jcin.2019.03.035
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1876-7605
EndPage 1252
ExternalDocumentID PMC6669893
31202947
Genre Multicenter Study
Research Support, N.I.H., Intramural
Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States
GeographicLocations_xml – name: United States
GrantInformation_xml – fundername: Intramural NIH HHS
  grantid: ZIA HL006040
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
18M
1B1
1P~
1~.
4.4
457
4G.
53G
5GY
5VS
7-5
8P~
AAEDW
AAIKJ
AALRI
AAOAW
AAQFI
AAXUO
AAYWO
ABBQC
ABFRF
ABJNI
ABMAC
ABMZM
ACGFO
ACGFS
ADBBV
ADEZE
ADVLN
AEFWE
AEKER
AEVXI
AEXQZ
AFCTW
AFETI
AFJKZ
AFRHN
AFTJW
AGCQF
AGYEJ
AITUG
AJRQY
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
BAWUL
BLXMC
CGR
CS3
CUY
CVF
DIK
EBS
ECM
EFKBS
EIF
EJD
F5P
FDB
FEDTE
FNPLU
GBLVA
HVGLF
IXB
J1W
M41
MO0
N9A
NPM
O-L
O9-
OAUVE
OA~
OK1
OL0
P-8
P-9
P2P
PC.
Q38
RIG
ROL
SDF
SEL
SES
SSZ
W8F
Z5R
7X8
5PM
ID FETCH-LOGICAL-p266t-ce46d474400614bb59d65c41bbb8826e89e2ffde0dbaee97e794aa6211c3cee73
ISSN 1876-7605
1936-8798
IngestDate Thu Aug 21 18:23:55 EDT 2025
Fri Jul 11 02:53:12 EDT 2025
Mon Jul 21 06:02:54 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 13
Keywords coronary artery obstruction
transcatheter aortic valve replacement
transcatheter electrosurgery
bioprosthetic heart valve failure
structural heart disease
Language English
License Published by Elsevier Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p266t-ce46d474400614bb59d65c41bbb8826e89e2ffde0dbaee97e794aa6211c3cee73
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Dr. Rogers has served as a consultant for Medtronic; and a physician proctor for Edwaids Lifesdences and Medtronic. Drs. Eng and Paone have served as proctors for Edwaids Lifesdences. Dr. Leshnower has served on the Medtronic Speakers Bureau. Dr. Waksman has served on the advisory board for Abbott Vasculai, Amgen, Boston Sdentific, Caidioset, Caidiovasculai Systems, Medtronic, Philips Volcano, and Pi-Cardia; has served as a consultant for Abbott Vasculai, Amgen, Boston Sdentific, Biotronik, Biosensors, Cardioset, Cardiovascular Systems, Philips Volcano, Pi-Cardia, and Medtronic; has received grant support from Abbott Vascular, AstraZeneca, Boston Sdentific, and Chiesi; has served on the Speakers Bureau for AstraZeneca and Chiesi; and is an investor in MedAlliance. Dr. Dvir has served as a consultant for Edwards Lifesdences, Medtronic, and Abbott Vascular. Drs. Khan, Rogers, and Lederman aie co-inventois on patents, assigned to the National Institutes of Health, on cathetei devices to lacerate valve leaflets. All other authors have reported that they have no relationships relevant to the contents of this paper to disdose. Lais Soendergaard, MD, served as the Guest Editor for this paper.
PMID 31202947
PQID 2242112232
PQPubID 23479
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6669893
proquest_miscellaneous_2242112232
pubmed_primary_31202947
PublicationCentury 2000
PublicationDate 2019-07-08
PublicationDateYYYYMMDD 2019-07-08
PublicationDate_xml – month: 07
  year: 2019
  text: 2019-07-08
  day: 08
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle JACC. Cardiovascular interventions
PublicationTitleAlternate JACC Cardiovasc Interv
PublicationYear 2019
References 31202952 - JACC Cardiovasc Interv. 2019 Jul 8;12(13):1253-1255. doi: 10.1016/j.jcin.2019.04.009.
References_xml – reference: 31202952 - JACC Cardiovasc Interv. 2019 Jul 8;12(13):1253-1255. doi: 10.1016/j.jcin.2019.04.009.
SSID ssj0060972
Score 2.6256058
Snippet The BASILICA (Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction during TAVR) investigational...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 1240
SubjectTerms Aged
Aged, 80 and over
Aortic Valve - diagnostic imaging
Aortic Valve - physiopathology
Aortic Valve - surgery
Aortic Valve Stenosis - diagnostic imaging
Aortic Valve Stenosis - physiopathology
Aortic Valve Stenosis - surgery
Bioprosthesis
Coronary Stenosis - diagnostic imaging
Coronary Stenosis - etiology
Coronary Stenosis - physiopathology
Coronary Stenosis - prevention & control
Feasibility Studies
Female
Heart Valve Prosthesis
Heart Valve Prosthesis Implantation - adverse effects
Heart Valve Prosthesis Implantation - instrumentation
Hemodynamics
Humans
Iatrogenic Disease - prevention & control
Male
Prospective Studies
Prosthesis Design
Prosthesis Failure
Risk Factors
Time Factors
Transcatheter Aortic Valve Replacement - adverse effects
Transcatheter Aortic Valve Replacement - instrumentation
Treatment Outcome
United States
Title The BASILICA Trial: Prospective Multicenter Investigation of Intentional Leaflet Laceration to Prevent TAVR Coronary Obstruction
URI https://www.ncbi.nlm.nih.gov/pubmed/31202947
https://www.proquest.com/docview/2242112232
https://pubmed.ncbi.nlm.nih.gov/PMC6669893
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELZYkBAXxGPZLS8VaW9VosRJnOTYBhAPFa3YgrhVduwsRTSt2nKAX89MnBSn6gG4RFXc1nK-0fgbZ-YbQv5IKQLPka6lOMSqPgTMVgTbuJUxz1NOwKOoqJDr3rCLO__qIXgwKq6xumQm7PRtaV3Jd1CFe4ArVsl-Adn5n8IN-Az4whUQhuunMe60_11iOXCrhxPWuGY7SWzM6KglnBo5jh_vcR71MegVzzLU9bFrWTmC617IbcmHrc58rMMFnpFMdJ7ePZ8OngfTVjIfvx39L_uv9Ubi1TxdKAqaLMd0iDEKFoe6U7St9D3woFbInKDmRalpLZ7hE4FBOMb-CoyKLvXd-hjhyX5KByhM62r1WS1mYoA5HhZoei51aKzVOhcUs_92EwjKYmBiP8gahfABO1ucXl5XOzRDySKdbaDXVhZT6by_xek3yHo117IoZDGZ1mAnvS2yWYYVzba2kW2yovIdst4tEyd2yTaYSrMylWZhKj_J3flZL7mwynYY1hhY1MxKlc-kj4KOGMULEcSSBanvCiEgTGIqihXNMqkcKbhScajA1XLOIMJPPaBCobdHVvNRrn6Tpod9CICYAD3JfJGGcepEikrOMjdkKY0a5KRaaB_cDb5D4rkavUz7FFMIXOCUtEF-6YX3x1oXpV89pgYJa49k_gWUMq-P5IPHQtK8xGv_2788IBsf5ntIVmeTF3UEdHEmjgvs3wHCHWRM
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+BASILICA+Trial&rft.jtitle=JACC.+Cardiovascular+interventions&rft.au=Khan%2C+Jaffar+M.&rft.au=Greenbaum%2C+Adam+B.&rft.au=Babaliaros%2C+Vasilis+C.&rft.au=Rogers%2C+Toby&rft.date=2019-07-08&rft.issn=1936-8798&rft.eissn=1876-7605&rft.volume=12&rft.issue=13&rft.spage=1240&rft.epage=1252&rft_id=info:doi/10.1016%2Fj.jcin.2019.03.035&rft_id=info%3Apmid%2F31202947&rft.externalDocID=PMC6669893
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1876-7605&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1876-7605&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1876-7605&client=summon